AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05109143 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indomethacin suppository
Description: 100mg Indomethacin Suppository administered at the time of Induction
Study NCT05109143 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Medical Treatment
Description: Standard Medical Treatment
Study NCT05109143 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Medical Treatment
Description: Standard Medical Treatment
Study NCT01684813 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prasugrel.
Description: Patients in this group will receive a loading dose of 60 mg prasugrel (6 x 10 mg tablets) followed by at least dose of 10 mg prasugrel (1 x 10 mg tablet). Beyond the second day after PCI, these patients will receive double antiaggregation therapy according to their physician´s criteria.
Study NCT01684813 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: Patients in this group will receive the standard dose of clopidogrel, a daily dose of 75 mg. Beyond the second day post-PCI, these patients will receive double anti aggregation therapy according to their physician's criteria.
Study NCT03171571 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Coaching procedure
Description: In this study, the volunteers will be followed during one year. The wellbeing will be followed with :~* survey like FFQ, SF36, dietary habits.~* actimetry measurement~* one year follow-up of weight, waist measurement~* nutritional biomarkers
Study NCT04182828 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: both the drugs will be prepared in same volume, color, consistency and appearance
Study NCT04182828 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lidocaine
Description: both the drugs will be prepared in same volume, color, consistency and appearance
Study NCT00515762 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: elasto-gel cap
Description: scalp cooling cap
Study NCT02280408 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal saline placebo.
Study NCT02280408 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V920
Description: Vesicular Stomatitis Virus (VSV)-based vaccine 1-mL injection containing 3x10\^6, 2x10\^7, or 1x10\^8 pfu.
Study NCT03248206 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: lifestyle changes
Description: Providing a home-based exercise program supervised by therapists can be an acceptable strategy with the characteristics of convenience and inexpensiveness to promote neuromuscular and functional component for the patients with diabetes mellitus.
Study NCT03248206 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: lifestyle changes
Description: Providing a home-based exercise program supervised by therapists can be an acceptable strategy with the characteristics of convenience and inexpensiveness to promote neuromuscular and functional component for the patients with diabetes mellitus.
Study NCT00526071 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: migalastat HCl
Study NCT05242627 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Clinical Firearm Safety Counseling Module
Description: The DGSOM class of 2024 will participate in a mandatory 1-hour module covering four main domains: (1) firearm epidemiology; (2) suicide epidemiology and introduction to means matter; (3) firearm counseling; and (4) an example of standardized patient encounter that includes a discussion of firearm safety with the patient. The module will be taught in combination by the study team, subject matter experts, and the DGSOM Standardized Patient Program.
Study NCT02743104 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Study NCT02743104 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Study NCT02743104 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: midazolam and atropine
Study NCT02743104 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Study NCT01680471 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam 0.03mg/kg
Description: This group will be injected intravenous midazolam 0.03mg/kg five minutes before the end of surgery.~If emergence agitation is severe, the patients will be treated by psychological support from the parents or nurse and intravenous fentanyl 1㎍/kg.
Study NCT01680471 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam 0.05mg/kg
Description: This group will be injected intravenous midazolam 0.05mg/kg five minutes before the end of surgery.~If emergence agitation is severe, the patients will be treated by psychological support from the parents or nurse and intravenous fentanyl 1㎍/kg.
Study NCT01680471 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: This group will be injected intravenous normal saline five minutes before the end of surgery.~If emergence agitation is severe, the patients will be treated by psychological support from the parents or nurse and intravenous fentanyl 1㎍/kg.
Study NCT02207452 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: He-3 MRI
Description: Hyperpolarised helium-3 Magnetic Resonance Imaging (MRI) scan pre-bronchodilator and 1 hour post-bronchodilator (after 1 hour post-bronchodilator assessments/procedures completed).
Study NCT02207452 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Salbutamol
Description: Salbutamol 5mg nebulised single dose
Study NCT02207452 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Ipratropium
Description: Ipratropium 500mcg nebulised single dose
Study NCT02207452 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: MRI
Description: Proton Magnetic Resonance Imaging (MRI) scan pre-bronchodilator and 1 hour post-bronchodilator (after 1 hour post-bronchodilator assessments/procedures completed).
Study NCT01072604 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (Aspirin, BAY1019036)
Description: One oral dose of new formula Aspirin Prototype 1 under fasting conditions
Study NCT01072604 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (Aspirin, BAY1019036)
Description: One oral dose of new formula Aspirin Prototype 2 under fasting conditions
Study NCT01072604 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetylsalicylic acid (Aspirin, BAYE4465)
Description: One oral dose of Aspirin Plain Tablet under fasting conditions
Study NCT01072604 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetylsalicylic acid (Aspirin, BAYE4465)
Description: One oral dose of Aspirin Dry Granules under fasting conditions
Study NCT01724632 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lifestyle Counseling
Description: Participants receive instructions for making healthy changes to their diet and physical activity habits.
Study NCT01724632 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle Counseling
Description: Participants receive instructions for making healthy changes to their diet and physical activity habits.
Study NCT00038818 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD8 Depleted Donor Lymphocyte
Study NCT03812276 — intervention group
Intervention type: DEVICE
Intervention: Dental Implants
Description: Dental Implants will be used according to standard routine in daily practice, according to all indications as specified by the manufacturer in the IFU (informations for use).
Study NCT00643162 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Lexapro
Description: 5mg-10mg of lexapro, daily, for 9 weeks for all study participants.
Study NCT00643162 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lexapro
Description: 5mg-10mg of lexapro, daily, for 9 weeks for all study participants.
Study NCT00643162 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Light touch
Description: Light touch twice a week, for 8 weeks
Study NCT00643162 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Massage
Description: Massage twice a week, for 8 weeks.
Study NCT00724087 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 5.5-hour bedtime
Description: 16 days with sleep allowed only during a 5.5-hour bedtime period at night
Study NCT00724087 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 8.5-hour bedtime
Description: 16 days with sleep allowed only during a 8.5-hour bedtime period at night
Study NCT04296838 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intravitreal injection of Conbercept
Description: patients will receive intravitreal injection of Conbercept, and at the same time, aqueous humor sample will be obtained from the anterior chamber to measure the concentrations of cytokines.
Study NCT02334462 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pfs230D1M-EPA/Alhydrogel
Study NCT02334462 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pfs25M-EPA/Alhydrogel
Study NCT02334462 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TWINRIX
Study NCT02334462 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Menactra
Study NCT02347137 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: step-reduction
Description: reduce daily physical activity to less than 1500 steps per day
Study NCT02347137 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: step-reduction
Description: reduce daily physical activity to less than 1500 steps per day
Study NCT02347137 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: step-reduction plus resistance exercise
Description: reduce physical activity to less than 1500 steps per day with thrice weekly low-load, high effort resistance exercise
Study NCT02347137 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: step-reduction plus resistance exercise
Description: reduce physical activity to less than 1500 steps per day with thrice weekly low-load, high effort resistance exercise
Study NCT02083913 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telehealth supervised exercise training
Description: Endurance and strength training (3x/week during 12 weeks)
Study NCT03021343 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colchicine
Description: colchicine given as per trial protocol
Study NCT04319588 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Parasternal Block+ Infiltration with local anesthetic of access to thoracic drainage
Description: After induction of general anesthesia we will perform an ultrasound-guided Parasternal Block in association with infiltration with local anesthetic of access to thoracic drainage at the end of the intervention.
Study NCT04319588 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Infiltration with local anesthetic of access to thoracic drainage
Description: Infiltration with local anesthetic of access to thoracic drainage at the end of the intervention.
Study NCT02470650 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: elvitegravir/cobicistat/emtricitabine/tenofovir
Description: 1 recovered tablet once Per day ● Specify total dose (number and unit): 150 mg de elvitegravir, 150 mg cobicistat, 200 mg emtricitabine , 245 mg tenofovir disoprox milligram(s)
Study NCT02470650 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Darunavir
Description: Darunavir 800 mg (Prezista®) 1 recovered tablet 800 mg once a day
Study NCT02470650 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: abacavir/lamivudine
Description: Abacavir 600 mg /lamivudine 300 mg recovered tablet once a day
Study NCT02470650 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ritonavir
Description: Ritonavir 100 mg recovered tablet once a day
Study NCT02470650 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lamivudine
Description: lamivudine 300mg (Epivir) 1 recovered tablet
Study NCT02470650 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rilpivirine
Description: rilpivirine (Edurant®) 1 recovered tablet 25 mg. once a day
Study NCT02546206 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic Yoghurt
Description: Probiotic yoghurt consumption
Study NCT02546206 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Natural Yoghurt
Description: Natural yoghurt consumption
Study NCT00975780 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Enhanced Oral Care
Description: oral brushing plus oral chlorhexidine plus upright feeding positioning
Study NCT00975780 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual oral care
Description: Usual oral care and feeding positioning
Study NCT01056016 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ADHD Collaborative
Description: This intervention includes mapping and redesign of office flow to facilitate adherence to AAP ADHD guidelines as well as didactic sessions related to diagnosis and treatment of ADHD. Didactics emphasize the importance of obtaining parent and teacher behavioral ratings (e.g. Vanderbilt ADHD Rating Scales) at the time of the initial assessment for ADHD and during follow-up after initiating medication treatment and making a DSM-IV based ADHD diagnosis. Practices are given a web-based ADHD portal to assist them in creating a patient registry and to help in obtaining parent and teacher ratings scales.
Study NCT02114073 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Description: In study arm, ophthalmic emulsion of cyclosporine A 2% will be prescribed in postoperative phase.
Study NCT02114073 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Betamethasone
Description: In control arm, betamethasone eye drop will be prescribed in postoperative period.
Study NCT03858309 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Breathing Group 1
Description: The 8-week breathwork intervention incorporates a set of breathing practices under the guidance of a certified yoga teacher.
Study NCT03858309 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Breathing Group 2
Description: The 8-week breathwork intervention incorporates a set of slow breathing practices under the guidance of a certified yoga teacher.
Study NCT04749992 — intervention group
Intervention type: PROCEDURE
Intervention: Polysomnographic examination in sleep laboratory (PSG measurement)
Description: Recording of sleep quality and quantity by sleep parameters, such as total sleep time - TST; duration of sleep stages - S1t, S2t, S3t, rapid eye movement - REMt; sleep onset latency - SL; wake after sleep onset - WASO, sleep efficiency - SE.
Study NCT02575157 — intervention group
Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: No intervention
Description: No intervention
Study NCT04249986 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: The Borg Rating of Perceived Exertion
Description: Participants who satisfy the exclusion criteria and health assessment instrument are categorized in the lowest risk group for cardiac events and does not require medical screening for mild to moderate exercise per ACSM guidelines.
Study NCT02891135 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SLATE
Description: Algorithm for collecting information required to determine if patient is eligible for immediate (same-day/same-visit) initiation of antiretroviral medications.
Study NCT03420352 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Thromboelastography
Description: paired TEG analysis undertaken from participants with the two different needles
Study NCT01103193 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: remifentanil injected
Description: mixture of 60% nitrous oxide and 40% oxygen is administered through a face mask. In the first group the patient receives a constant concentration of sevoflurane. In this group the remifentanil concentration will be injected via an intravenous line in a step up protocol.
Study NCT01103193 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sevoflurane in step up concentration
Description: of 60% nitrous oxide and 40% oxygen is administered through a face mask.remifentanil is injected in a fixed rate and sevoflurane is administered in a step up concentration.
Study NCT00946387 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron HCl 24 mg Tablets (Sandoz, Inc.)
Study NCT00946387 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zofran (Ondansetron HCl) 24 mg Tablets (GlaxoSmithKline)
Study NCT00925457 — intervention group
Intervention type: OTHER
Intervention: No Intervention
Description: Neither current domperidone nor current PPI
Study NCT00925457 — intervention group
Intervention type: DRUG
Intervention: Current Domperidone
Description: Current domperidone at any dose, regardless of proton pump inhibitor status
Study NCT00925457 — intervention group
Intervention type: DRUG
Intervention: Current proton pump inhibitor (PPI)
Description: Current PPI and not current dapoxetine
Study NCT03855059 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: This will be a saline solution of given IV or perineural.
Study NCT03855059 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone Sodium Phosphate
Description: This will be the active drug solution given IV or perineural.
Study NCT04847336 — intervention group
Intervention type: OTHER
Intervention: No intervention is planned
Description: No intervention is planned
Study NCT00573300 — intervention group
Intervention type: PROCEDURE
Intervention: Phlebotomy
Description: Single blood draw
Study NCT00060840 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nitric Oxide
Description: 40 ppm of Nitric Oxide continuously administered for 48 hours
Study NCT00060840 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nitrogen
Description: Nitrogen (N2) administered at 40 ppm for 48 hours
Study NCT02740452 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: ligamys technique
Description: Ligamys technique (device) or standard technique
Study NCT02740452 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: standard technique (anatomic reconstruction)
Description: Ligamys technique (device) or standard technique
Study NCT00691834 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Intracoronary delivery of unfractionated bone marrow mononuclear cells
Description: Maximal intracoronary cell dose: 50 x 10e7 cells diluted in 10 ml Maximal intracoronary volume: 10 ml (diluted in plasma and culture medium)
Study NCT00691834 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Plasma and culture medium (10 ml)
Study NCT01688349 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: analyze the role of glucocorticoid in AT distribution.
Description: The purpose of this trial is to investigate the impact of cortisol on adipose tissue functions, distribution and morphology. Patient with endogenous blood cortisol excess exhibit changes in adipose tissue, with fat gain in the upper trunk, face and neck leading to visceral obesity and features of the metabolic syndrome. The aims of this study will be~* to compare the pattern of gene expression between visceral and subcutaneous adipose tissue in Cushing patients requiring an adrenalectomy as cortisol adenoma treatment;~* to compare these patterns of gene expression with those of two control populations:1/ healthy metabolic subjects having a partial nephrectomy, 2/obese patients with similar degree of insulin resistance.
Study NCT01688349 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: analyze the role of glucocorticoid in AT distribution.
Description: The purpose of this trial is to investigate the impact of cortisol on adipose tissue functions, distribution and morphology. Patient with endogenous blood cortisol excess exhibit changes in adipose tissue, with fat gain in the upper trunk, face and neck leading to visceral obesity and features of the metabolic syndrome. The aims of this study will be~* to compare the pattern of gene expression between visceral and subcutaneous adipose tissue in Cushing patients requiring an adrenalectomy as cortisol adenoma treatment;~* to compare these patterns of gene expression with those of two control populations:1/ healthy metabolic subjects having a partial nephrectomy, 2/obese patients with similar degree of insulin resistance.
Study NCT04178785 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil
Description: Patients electively admitted for laparoscopic hysterectomy will be approached for requirement. After obtaining a written informed consent, patients will be randomly assigned either to the study group (Remifentanil group) or to the control group (Fentanyl group) in a 1:1 ratio.
Study NCT01681719 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: WBV and Resistance
Description: use of WBV and resistance device during 03 months in elderly health people. The WBV used progressive increases of time and amplitude and the resistance training improves the weight.~For Resistance: performed in upper and lower limbs in weight machine Mega II Movement®, used guidelines from American College of Sports Medicine for elderly, with two series of 08 repetitions (75% weight of one RM), considered for RM calculation the maximum voluntary isometric contraction.~For WBV: used MY3 platform (Power Plate®, MY3, UK) frequency 35 hertz, tri-axial, amplitude 02 mm in adaptation and initial phases, increasing to 04 mm in phases intermediate and final. The time initial was 10 minutes, progressed to 15 min in second month, concluding with 20 min. Rest time between series remained 01 min.